CEND-1 Offers Hope in Advanced Pancreatic Cancer
Phase I study showed good safety profile, no dose-limiting toxicities, and encouraging activity
Source: medpagetoday.com
Stay updated with breaking news from Christoph Springfeld. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Phase I study showed good safety profile, no dose-limiting toxicities, and encouraging activity
Fatigue 17 3 12 2 Lipase increased 17 3 17 2 Anaemia 16 5 2 - Amylase increased 15 1 13 1 Nausea 12 1 7 - Vomiting 12 3 4 - Oedema peripheral 11 - 9 - Abdominal pain 10 2 1 -... | October 7, 2021